Logo-jcvtr

J Cardiovasc Thorac Res. 2018;10(3): 149-152. doi: 10.15171/jcvtr.2018.24
PMID: 30386535        PMCID: PMC6203872

Original Article

Comparison between rosuvastatin and atorvastatin for the prevention of contrast-induced nephropathy in patients with STEMI undergoing primary percutaneous coronary intervention

Ata Firouzi 1, Ali Kazem Moussavi 1, Ahmad Mohebbi 1, Mohammad Javad Alemzadeh-Ansari 1 * , Reza Kiani 1, Hamid Reza Sanati 1, Bahram Mohebbi 1, Farshad Shakerian 1, Ali Zahedmehr 1, Mohammad Mostafa Ansari-Ramandi 1, Saeed Oni Heris 1, Bahar Ghaleshi 1, Fatemeh Ghorbani 1

Cited by CrossRef: 8

1- Dai Y, Huang J, Zeng L, Huang Z, Duan C, Shao S, Chen H, Xue L, Chen J, Tan N, He P, Liu Y, Yu D. Comparison of the preventive efficacy of rosuvastatin versus atorvastatin in post-contrast acute kidney injury in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. Biomedicine & Pharmacotherapy. 2020;128:110336 [Crossref]
2- Golshani S, Tavasoli P, Farsavian A, Farsavian H, Charati J. Comparison of the incidence of contrast-induced nephropathy after primary PCI in patients receiving high-dose rosuvastatin and atorvastatin. 2022;11(5):1957 [Crossref]
3- Toso A, Leoncini M, Maioli M, Tropeano F, Villani S, Bellandi F. A Prospective, Randomized, Open-Label Trial of Atorvastatin versus Rosuvastatin in the Prevention of Contrast-Induced Acute Kidney Injury, Worsened Renal Function at 30 Days, and Clinical Events After Acute Coronary Angiography: the PRATO-ACS-2 Study. Cardiorenal Med. 2020;10(5):288 [Crossref]
4- Arware A, Nayak V, Chogtu B, Belle V, Verma S. Antiinflammatory and Antioxidant Mediated Nephroprotection of Melatonin and Rosuvastatin in Carboplatin Induced Nephrotoxicity: An Experimental Study. Biomed Pharmacol J. 2024;17(3):1921 [Crossref]
5- Zhou Y, Chen L, Du X. Efficacy of short-term moderate or high-dose statin therapy for the prevention of contrast-induced nephropathy in high-risk patients with chronic kidney disease: systematic review and meta-analysis. Clinics. 2021;76:e1876 [Crossref]
6- Chen W, Fan Z, Huang C, Han Z, Liu J, Shi Z. Enhanced-Dose Statins for ST-Segment Elevation Myocardial Infarction Patients after Emergency Percutaneous Coronary Intervention. Disease Markers. 2022;2022:1 [Crossref]
7- Jones J, Tuite P, Guttendorf J. Use of Prophylactic High-Dose Statin Therapy to Reduce Contrast-Induced Acute Kidney Injury in Adults Undergoing Acute Coronary Angiography. Dimens Crit Care Nurs. 2023;42(5):295 [Crossref]
8- Qiao L, Wang S, Jia Q, Bian J, Fan Y, Xu X. Clinical efficacy and safety of statin treatment after carotid artery stenting. Artificial Cells, Nanomedicine, and Biotechnology. 2019;47(1):3110 [Crossref]
9- He W, Cao M, Li Z. Effects of different doses of atorvastatin, rosuvastatin, and simvastatin on elderly patients with ST‐elevation acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI). Drug Development Research. 2020;81(5):551 [Crossref]
10- Zhang J, Wang J, Yu H, Wang G, Zhang J, Zhu R, Liu X, Li J. Comparison between Atorvastatin and Rosuvastatin on Secondary Percutaneous Coronary Intervention Rate and the Risk Factors in Patients with Coronary Heart Disease. CDM. 2020;21(10):818 [Crossref]
11- Toso A, Leoncini M, Maioli M, Bellandi F. Pharmacologic Prophylaxis of Contrast-Induced Nephropathy. Interventional Cardiology Clinics. 2020;9(3):369 [Crossref]